Full-Time

Senior Director – Brand Strategy Lead

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

No salary listed

Expert

Cambridge, MA, USA

Hybrid

Role is based in Cambridge, MA, or hybrid. Ability to travel 25% as needed.

Category
Brand & Creative Marketing
Growth & Marketing
Required Skills
Branding/Brand Strategy
Risk Management
Requirements
  • BS/BA in a relevant academic field; MBA, MD, PhD, or other graduate degree strongly preferred.
  • Minimum 12 years business experience within the pharma/biotech/biopharma space.
  • Proven track record of developing and executing brand strategies in highly cross-functional environments.
  • Experience in cell therapy is a must.
  • U.S. launch experience is a must.
  • Outstanding strategic thinking and problem-solving capabilities.
  • Must be capable of managing and prioritizing multiple activities.
  • Can operate in two worlds — big picture orientation with attention to detail.
  • Exceptional interpersonal skills and collaborative nature with strong ability to influence, motivate, inspire, encourage and develop others.
  • Demonstrated people management experience and development capabilities required.
  • Builds effective teams that work well across functions and groups.
  • Strong business and financial capabilities.
  • Advanced communication and presentation skills required.
Responsibilities
  • Develops and leads brand strategy for BEAM-101 and ensures alignment across key cross-functional stakeholders including Medical, Market Access, and Technical Operations.
  • Owns development of brand positioning, messaging, and competitive strategy.
  • Leads commercial launch readiness and execution in close collaboration with cross-functional partners.
  • Directs HCP marketing strategy and oversees tactical execution by agency partners and future HCP marketers.
  • Builds and leads team of marketing professionals.
  • Oversees generation of customer and market insights through primary and secondary research, competitive intelligence and Advisory Boards.
  • Leads scenario planning, risk management, and contingency strategies for launch, including forecasting and supply chain coordination.
  • Budget management.
Desired Qualifications
  • Experience in both large and small company environments a plus.

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise changes to the genetic code to correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests heavily in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and potential commercialization of their treatments after regulatory approval. Beam Therapeutics distinguishes itself from competitors by its commitment to rigorous scientific development and a values-driven approach, emphasizing the importance of its expert team in advancing genetic medicine. The ultimate goal of the company is to deliver lasting cures for patients suffering from genetic conditions.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Beam raised $500 million, boosting its financial resources for R&D.
  • Regulatory support for genetic therapies benefits Beam's base editing advancements.
  • Growing interest in base editing technology enhances Beam's market potential.

What critics are saying

  • Competition from CRISPR-based therapies may impact Beam's market share.
  • New CFO appointment could lead to transitional financial management challenges.
  • Reliance on partnerships exposes Beam to risks if collaborations underperform.

What makes Beam Therapeutics unique

  • Beam Therapeutics uses base editing, a precise alternative to CRISPR technology.
  • The company focuses on lifelong cures for genetic disorders like sickle cell disease.
  • Beam's base editing avoids double-stranded DNA breaks, enhancing safety and precision.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
Network News Wire
May 23rd, 2025
Networknewsbreaks - Beam Therapeutics Inc. (Nasdaq: Beam) To Present New Sickle Cell Data From Beacon Trial At Eha2025

Beam Therapeutics (NASDAQ: BEAM), a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated data from its BEACON Phase 1/2 trial of BEAM-101 at the European Hematology Association 2025 Congress, June 12-15 in Milan. BEAM-101 is an investigational, one-time ex vivo cell therapy targeting severe vaso-occlusive crises in sickle cell disease (SCD). The new data, covering safety and efficacy outcomes in 17 patients, will be highlighted during multiple poster sessions on June 13, underscoring BEAM-101’s potential to provide a durable treatment by addressing the root cause of SCD. Additional presentations will explore biomarkers, manufacturing advances, and red blood cell health post-treatment. Beam will also host a webcast on June 13 at 4:00 p.m. ET to review EHA highlights. To view the full press release, visit https://nnw.fm/taUAe About Beam Therapeutics Beam Therapeutics (NASDAQ: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines

Benzinga
Mar 10th, 2025
Beam Therapeutics Reports Data, Raises $500M

Beam Therapeutics announced promising initial safety and efficacy data from its Phase 1/2 trial of BEAM-302 for treating alpha-1 antitrypsin deficiency (AATD). The trial showed BEAM-302 was well tolerated and led to dose-dependent correction of the disease-causing mutation. Beam plans to continue the trial and report further data in 2025. Additionally, Beam raised $500 million through an equity offering. BEAM stock was down 3.44% at $27.50 in premarket trading.

GlobeNewswire
Mar 10th, 2025
Beam Therapeutics Announces Pricing of Underwritten Offering

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

GlobeNewswire
Dec 6th, 2024
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024.

CityBiz
Jul 15th, 2024
Beam Therapeutics Chief Financial Officer Terry-Ann Burrell to Retire

CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase.